Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 5Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Glioblastoma 4Carcinoma, Renal Cell 4Sarcoma, Alveolar Soft Part 3Sarcoma 3Gliosarcoma 3Fallopian Tube Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Solitary Fibrous Tumor, Pleural 2Mesothelioma, Malignant 2Colorectal Neoplasms 2Carcinosarcoma 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neoplasm Metastasis 1

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fallopian Tube Mucinous Adenocarcinoma × cediranib × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡